RESUMO
The aim of the present study was to assess the use of an alternative molecular approach for p53 mutation detection and to investigate the usefulness of p53 as a prognostic indicator in bladder cancer. We applied the NIRCA assay, which consists of two-step PCR amplification, transcription of the amplified sequence, hybridisation of the transcripts and treatment with RNAses which recognizes mismatches due to the presence of mutations. Results of molecular analysis are correlated with immunohistochemical findings, standard clinopathological parameters and survival. p53 mutations were detected in 42.4% of the 66 examined TCCs cases. We could not demonstrate any statistical relationship between the presence of p53 mutation and p53 protein overexpression, and tumor stage or grade. A trend towards higher mutation rate in higher grade tumours was observed, although this failed to reach statistical significance. Despite the observation that the alterations of p53 gene are associated features of aggressive phenotype of transitional cell carcinomas they do not seem to offer additional prognostic information.
